Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
ProstACT SELECT trial: what clinicians have said so far
177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study
- NCT04786847 ↗
- Completed
- Telix Pharmaceuticals (Innovations) Pty Limited
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on ProstACT SELECT (177Lu-DOTA-TLX591 in PSMA-expressing metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ProstACT SELECT so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Safety, Tolerability, Biodistribution, Dosimetry and Efficacy Study of 177Lu-DOTA-TLX591 With Best Standard of Care in Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Metastatic Prostate Cancer
- Interventions
- 177Lu-DOTA-TLX591
- Arms
- Single administration of 177Lu-DOTA-TLX591 · Experimental
- Enrollment
- 30
- Primary outcomes
- Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Start
- Jan 30, 2022
- Primary completion
- Sep 30, 2023
- Results posted
- No
- Registry record
- NCT04786847 · updated Feb 12, 2024